In this edition of You Make the Call, your patient presents with worsening plaque psoriasis (>8% BSA) now affecting his scalp and bilateral upper extremities after failing effective treatment with narrowband UV-B and topical corticosteroid combination therapy. How would you approach treatment?
The decision to start a patient with psoriasis onto a systemic agent for disease management is an important conversation between provider and patient. When considering a biologic for the treatment of plaque psoriasis, what is the most important factor in your clinical decision?
Immunomodulating therapies can help a majority of patients receiving the therapy achieve and maintain Psoriasis Area and Severity Index 100 scores for short- and long-term periods of time. How have newer biologics impacted your practice? Let us know!
From do-it-yourself skin care to sunburn tattoos and perineum sunning (yes, you read that right), 2019 has had a lot of new and questionable trends. Which ones have you seen personally, either in your practice or on social media?